Navigation Links
Pharmaceutical Industry Veteran is Appointed CMO at Kinex Pharmaceuticals
Date:2/25/2010

BUFFALO, N.Y., Feb. 25 /PRNewswire/ -- Kinex Pharmaceuticals has appointed Rudolf Kwan, MD, as Chief Medical Officer.  

Dr. Kwan has had a successful career in the pharmaceutical industry and brings to Kinex over twenty years of experience in clinical operations.  Most recently he served dual roles at Schering Plough (SP) as Vice President and Regional Head of Asia Pacific Global Clinical Operations and Vice President of Global Clinical Development, CNS.

In the clinical operations position, Dr. Kwan successfully recruited Heads of Clinical Operations for China, South East Asia, Australia, Taiwan and South Korea and set up the infrastructure to conduct global clinical trials in Asia Pacific.  

As Vice President of Global Clinical Development, CNS, Dr. Kwan was responsible for the clinical development of all SP central nervous system drugs, globally. Major achievements included developing and executing a bioequivalence registration strategy for a new formulation of Temodol, for glioblastoma, which led to a simultaneous global registration.  He also designed and executed multiple phase 2 development programs.

Earlier at Schering Plough, Dr. Kwan held various clinical operation positions with increasing responsibility.  He held similar positions at Chiron Corporation and at Smith Kline Beecham.

Dr. Kwan obtained an MD degree in Hong Kong and did subsequent training in England.  He has served as Chair of the Data Monitoring and Safety Board for the National Institute on Deafness and other Communication Disorders for trials on Celecoxib as an adjunct to surgery for Recurrent Respiratory Papillomatosis. Currently, he is a member and Chair, of the Data Monitoring and Safety Board and Protocol Review Board for the Clinical Trial Network of the National Institute on Drug Abuse (NIDA) of the National Institute of Health.  He is also a member of several advisory panels and grant review panels for NIDA.

"Kinex Pharmaceuticals is extremely pleased to announce that Dr. Rudolf Kwan is joining us as Chief Medical Officer.  He brings with him a distinguished career of achievements in clinical operations in the pharmaceutical industry," said Dr. Allen Barnett, CEO of Kinex.  

At Kinex Pharmaceuticals, Dr. Kwan will be responsible for the design and execution of the Company's clinical development programs.  In 2010, Kinex will be launching several Phase 2 studies in oncology for KX2-391 as well as a Phase 1 trial in brain cancer for KX2-361.  "Dr. Kwan's appointment comes at a critical point in our Company's development as we transition from a drug discovery company to a development company with multiple compounds in clinical development," said Dr. Barnett.

About Kinex Pharmaceuticals

Kinex is a Buffalo, NY based, privately held biopharmaceutical company committed to the discovery and development of novel therapeutics. The Company's platform technologies, Mimetica™ and Opal™, provide unique insight into the design and synthesis of target-based small molecule inhibitors that selectively act on proteins that play key roles in cancer and immuno-inflammatory diseases.

KX2-391 is currently being studied in a Phase 2 clinical trial in prostate cancer patients; additional Phase 2 oncology studies will commence later in 2010. KX2-361 is being developed for brain cancer; an IND is expected during the 4th quarter of 2010. In addition, Kinex is developing several other new product candidates that inhibit key immuno-inflammatory pathways.

For more information, visit www.kinexpharma.com.

SOURCE Kinex Pharmaceuticals

Back to top

RELATED LINKS
http://www.kinexpharma.com

'/>"/>

SOURCE Kinex Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kinex Pharmaceuticals Initiates a Phase 2 Clinical Trial of KX2-391 in Patients with Prostate Cancer
2. Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009
3. Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results
4. Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility
5. Jazz Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on March 3, 2010
6. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
7. Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010
8. Innovative University of Cincinnati Program Trains Next Generation of Pharmaceutical Professionals
9. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Its Second Quarter of Fiscal Year 2010
10. Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains
11. Ritter Pharmaceuticals Joins NIH Conference Discussions on Lactose Intolerance and Associated Health Risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... International plc (NASDAQ: ENDP ) will announce its second-quarter ... senior management team will host a conference call and webcast before ... The dial-in number to access the call is U.S./ ... is 45397076. Please dial in 10 minutes prior to the scheduled ... of the call will be available from August 8, 2017 at ...
(Date:7/12/2017)... 2017 CarpalAID is a revolutionary new product that relieves ... Carpal tunnel syndrome affects more than 8 million people a ... of men. The common methods of treating CTS are painful surgery, ... braces or gloves. ... CarpalAID is a clear patch worn on the palm ...
(Date:7/11/2017)... , July 11, 2017  Sysmex America, Inc., ... diagnostic testing equipment as well as middleware information ... way to make quality assurance easier and more ... is well known for the innovation that it ... Monitor elevates quality assurance processes to a new ...
Breaking Medicine Technology:
(Date:7/20/2017)... ... ... ChenMed , a leading provider of value-based care for seniors, today announced ... Chief Medical Officer. Dr. McCarter, formerly Associate Professor of Family Medicine at the ... for the UVA Health System, brings 30 years of highly relevant experience to his ...
(Date:7/20/2017)... ... July 20, 2017 , ... For individuals with extended ... The adjustable beds used in such facilities are specially designed to accommodate patients with ... support. , An inventor from Rochester, Ind., has invented the patent-pending PORTABLE ARM ...
(Date:7/20/2017)... ... July 20, 2017 , ... Vixiar Medical, Inc. , ... systems for monitoring cardiopulmonary diseases, announced today that it has raised seed round ... submissions and fund final engineering and initial production of the Company’s first product, ...
(Date:7/20/2017)... ... July 20, 2017 , ... TCGRx announced ... its existing adherence automation lines. The ATP® Mini and InspectRx® Mini ... TCG’s standard products, but at a size and price point that can help ...
(Date:7/20/2017)... ... July 20, 2017 , ... A budget proposal to switch ... of - living - adjustment (COLA) is a bad deal for older and disabled ... price index (CPI) would grow even more slowly than the conventional one that is ...
Breaking Medicine News(10 mins):